SAGE Overview
Upcoming Projects (SAGE)

Don’t see a project related to the company you care about? Create your own!
Executed Projects (SAGE)

Discussing how access and pricing are being considered for Zurzuvae (zuranolone).
Ticker: SAGE
Executed On: Jan 16, 2024 at 01:30 PM EST 
Discussing the potential of Marinus' ganaxolone in Refractory Status Epilepticus and the RAISE trial
Tickers: MRNS, SAGE
Executed On: Oct 03, 2023 at 02:30 PM EDT 
Digging into the results from the P3 CORAL study of Biogen and Sage Therapeutics' Zuranolone in patients with major depressive disorder before PDUFA on Aug 5th
Tickers: SAGE, BIIB
Executed On: Jul 18, 2023 at 01:00 PM EDT 
Examining Sage Therapeutic's SAGE718 in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease and its recent Phase 2 LUMINARY trial results presented at AAN
Ticker: SAGE
Executed On: Apr 28, 2022 at 04:15 PM EDT 
A discussion of zuranolone in MDD: As data continues to be released what does the CORAL study say about the drug's future?
Ticker: SAGE
Executed On: Mar 08, 2022 at 12:00 PM EST 
Discussing the potential of Zuranolone (SAGE217) in Major Depressive Disorder before NDA expected in the 2nd Half of 2022
Ticker: SAGE
Executed On: Jan 27, 2022 at 04:00 PM EST
Expired Projects (SAGE)

Preview ph3 ganaxolone in Refractory Status Epilepticus (RSE) for 1Q24: Examining ph.2 data and RSE landscape
Tickers: MRNS, SAGE
Execute By: Oct 06, 2023 
Discussing Sage’s SAGE718 in Alzheimer’s Disease Dementia
Ticker: SAGE
Execute By: May 31, 2022 
Analyzing Marinus’ Ganaxolone in treating Postpartum Depression, after its Phase 2 Magnolia and Amaryllis trials data
Tickers: MRNS, SAGE
Execute By: Aug 28, 2018
Upcoming & Overdue Catalysts (SAGE)

Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SAGE)

Phase 1 biomarker data of Sage Therapeutics' (SAGE) SAGE718 in Huntington's disease due July 2019
Ticker: SAGE
Occurred on: Jul 24, 2019 
Phase 1 MAD data of Sage Therapeutics' (SAGE) SAGE324 in Essential tremor due July 2019
Ticker: SAGE
Occurred on: Jul 24, 2019 
SAGE 547 May Not Go On Sale Until 2018 (Assuming FDA Approval; PDUFA Dec 19 2018)
Ticker: SAGE
Occurred on: Nov 20, 2018 
SAGE Expects NDA Filing for SAGE 547 2nd Half of 2017
Ticker: SAGE
Occurred on: Apr 23, 2018 
Phase 2 TopLine Data for SAGE217 in Postpartum Depression due H2 2017
Ticker: SAGE
Occurred on: Apr 17, 2018 
Phase 2 OpenLabel Data Evaluating SAGE217 in Major Depressive Disorder Due H1 2017
Ticker: SAGE
Occurred on: Dec 07, 2017 
SAGE TopLine Phase 3 Data Evaluating SAGE547 in Moderate and Severe Postpartum Depression due H2 2017
Ticker: SAGE
Occurred on: Nov 09, 2017 
Phase 2 OpenLabel Data Evaluating SAGE217 in Parkinson's Disease Due H1 2017
Ticker: SAGE
Occurred on: Nov 02, 2017 
Phase 2 TopLine Data Evaluating SAGE217 in Essential Tremor Due H2 2017
Ticker: SAGE
Occurred on: Nov 02, 2017 
EMA Scientific Advice for SAGE547 in Postpartum Depression Due H1 2017
Ticker: SAGE
Occurred on: Aug 03, 2017 
SAGE's First NMDA Program (SAGE 718) Could Enter Clinical Trials Mid2017
Ticker: SAGE
Occurred on: Apr 27, 2017 
Topline Data from Phase 2 ProofofConcept Trial of SAGE217 in Parkinson's Disease
Ticker: SAGE
Occurred on: Feb 13, 2017 
Sage Therapeutics (SAGE) Announces Initiation of Phase 2 Clinical Development for SAGE217 in Mood Disorders
Ticker: SAGE
Occurred on: Dec 19, 2016 
SAGE Plans to Initiate Phase 2 Trials for SAGE 217 (Essential Tremors and Orphan Epilepsies) 2nd Half of 2016
Ticker: SAGE
Occurred on: Dec 13, 2016 
Sage Receives FDA Breakthrough Therapy Designation for SAGE547 for the Treatment of Postpartum Depression
Ticker: SAGE
Occurred on: Sep 06, 2016
Strategic Initiatives (SAGE)

Don’t see a strategic initiative related to the company you care about? Create your own!